Amphastar Pharmaceuticals Balances Growth Plans With Margin Risks

Amphastar Pharmaceuticals Inc ((AMPH)) has held its Q4 earnings call. Read on for the main highlights of the call.

Amphastar Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone, balancing strong growth from newer products and a robust cash position against pressure on legacy drugs and looming margin compression. Management highlighted resilient demand for BAQSIMI and Primatene MIST and a deepening pipeline, but acknowledged that pricing erosion and rising costs will weigh on profitability over the next year.

Full-Year Revenue and Growth Engines

Full-year 2025 net revenue came in at $719.9 million, down 2% year over year, underscoring the drag from older products. BAQSIMI remained the standout, generating $185.4 million, up 12%, while Primatene MIST added $108.7 million, up 7%, supported by steady demand and brand strength. New launches such as iron sucrose added incremental growth.

FDA Wins and a High-Value Exclusive Launch

The company secured multiple FDA approvals in 2025, including iron sucrose, teriparatide and ipratropium bromide HFA (AMP-007). AMP-007 received 180 days of generic exclusivity as the first Paragraph IV filer, with a commercial launch expected in early Q2 2026 targeting the roughly $112 million Atrovent HFA market and representing a significant near-term respiratory growth catalyst.

Cash Generation and Shareholder Returns

Operating cash flow reached $156.1 million for the year, reinforcing Amphastar’s capacity to fund growth projects and shareholder returns. The balance sheet held more than $300 million in cash and short-term investments, and management pointed to an active share repurchase strategy, having bought back about $75 million in stock previously with roughly $15 million still authorized.

BAQSIMI’s Strong Q4 Momentum

BAQSIMI continued to deliver in the fourth quarter, with sales up 12% year over year to $46.7 million. Growth was driven by higher U.S. unit volumes and the transition to direct global distribution, which helped Amphastar capture more of the value chain and deepen its positioning in ready-to-use rescue glucagon.

Broader Product Portfolio Gains

Beyond flagship brands, other pharmaceutical revenues grew 8% in Q4 to $62.4 million as albuterol and the newly launched iron sucrose gained traction. Albuterol benefited from strong market-driven demand, while iron sucrose’s early uptake signaled the potential for further expansion in hospital and clinic settings.

Pipeline Push into High-Value Markets

Management emphasized an expanded proprietary pipeline featuring three novel peptides in oncology and ophthalmology, plus a synthetic corticotropin program in immunology. Additional programs, including AMP-105, AMP-109, AMP-110 and AMP-107, are collectively estimated to unlock more than $60 billion in addressable market opportunity over time.

Progress on Near- and Mid-Term Blockbusters

Two advanced programs, insulin aspart BLA (AMP-004) and GLP-1 ANDA (AMP-018), are moving through regulatory pathways. Amphastar expects commercialization in 2027, positioning these assets as meaningful value drivers in insulin and GLP-1 markets that could transform the company’s revenue mix and competitive profile.

Manufacturing Scale-Up for Future Growth

To support its pipeline and complex generics, Amphastar plans a significant expansion of its Rancho Cucamonga facility that will quadruple production capacity. Capital spending is set to ramp in 2026, funded from internal cash generation, and is expected to enhance supply reliability and scalability as new products reach the market.

Top-Line Pressure from Legacy Products

The modest 2% revenue decline for the full year reflects heavier-than-expected headwinds in legacy injectables. Management cited pricing pressure across older categories as a key factor, signaling that while newer products grow, they are still in the process of fully offsetting erosion in mature lines.

Sharp Glucagon Contraction

Glucagon sales were a major weak spot, plunging 45% in Q4 to $14.1 million from $25.6 million. The decline stems from increased competition and a structural market shift toward ready-to-use products like BAQSIMI, highlighting both cannibalization and the broader transition in emergency glucagon treatment.

Epinephrine and Other Legacy Headwinds

Epinephrine multi-dose vial sales fell 9% in Q4 to $17.1 million amid heightened competition, compounding pressure on the legacy portfolio. Management also flagged continued pricing and volume headwinds for glucagon, the epi vial and phytonadione, with further sales declines expected in 2026 as these products face intense generic rivalry.

Profitability Hit by Earnings Declines

Net income in Q4 dropped to $24.4 million, or $0.51 per share, from $38.0 million, or $0.74 per share, a year earlier. Adjusted net income also declined to $34.2 million, or $0.73 per share, from $47.2 million, or $0.92 per share, reflecting revenue softness, pricing pressure and higher operating investments.

Margins at Risk in 2026

Gross margin held flat at 47% in Q4, but management cautioned that 2026 margins will be lower. Key drivers include price erosion in high-margin legacy drugs, rising input and labor costs and a greater contribution from lower-margin API sales at the China ANP subsidiary, all of which could compress profitability even as revenue grows.

Higher Operating Spend to Support Growth

Operating expenses climbed sharply, with general and administrative costs up 27% in Q4 to $16.5 million due to legal spending and ERP implementation. Research and development rose 29% to $23.3 million as Amphastar accelerates clinical programs and proprietary pipeline investments, prioritizing long-term growth over near-term margin expansion.

Optimizing BAQSIMI’s Global Footprint

To improve profitability, the company plans to exit several unprofitable international BAQSIMI markets once a three-year commitment ends in July. This will reduce international volume and partially offset U.S. growth in 2026, but management expects a healthier overall profit profile for the franchise as it focuses on core markets.

Uncertainty Around AMP-007 Upside

While AMP-007 benefits from a 180-day exclusivity window, management acknowledged uncertainty over the potential entry of an authorized generic, which could limit share capture. Continued generic competition across respiratory products adds risk, though the Atrovent HFA market still offers a meaningful revenue opportunity during the exclusivity period.

Guidance and Outlook for 2026

For 2026, Amphastar guided to mid- to high-single-digit revenue growth, driven by BAQSIMI, a rebound in Primatene MIST and the early Q2 launch of AMP-007. However, the company warned that gross margins will fall below the current 47% as legacy product pricing erodes and input costs rise, while S&M and R&D creep higher and capital spending ramps for the Rancho Cucamonga expansion, funded by strong cash flow and a sizable cash reserve.

Amphastar’s earnings call painted a picture of a company in transition, leaning on innovative products, a growing pipeline and manufacturing expansion to offset legacy drag. For investors, the story combines near-term margin pressure and earnings volatility with clear longer-term growth drivers, making execution on launches like AMP-007 and the 2027 biologics wave critical to unlocking value.